Recently, there has been frequent good news in the API industry
.
On November 24, Lukang Pharmaceutical issued an announcement that the API doxofylline received the "Notice of Approval of Marketing Application for Chemical APIs"
issued by the State Food and Drug Administration.
Doxofylline is a derivative of a new generation of methylxanthines used primarily to treat bronchial asthma, wheezing bronchitis, and dyspnea caused by other bronchospasm
.
The development of the API market continues to improve, what is the impact on pharmaceutical enterprises? (Image source: Pharma Network)
On November 21, Red Sun Pharmaceutical also announced that Tianjin Red Sun Jiandakang Pharmaceutical Technology Co.
, Ltd.
("Red Sun Jiandakang"), a shareholding subsidiary of the company, recently received the "Drug Registration Certificate"
for tosylamamide injection approved and issued by the National Medical Products Administration.
In addition, Frontier Biotech also said a few days ago that the company signed a supplementary procurement contract with a domestic biopharmaceutical company for the procurement of iconin (generic name: ebovital) APIs, and the contract stipulates that the total procurement amount of Ekonin APIs from 2022 to 2024 will not exceed 180 million yuan, and the maximum amount of contract procurement exceeds 50%
of the company's audited operating costs in the past fiscal year.
It is worth noting that from the recent developments such as the listing of products of enterprises in the API industry, the commissioning of bases and the acquisition of overseas certificates, it is obvious that enterprises have confidence
in laying out the API track.
In fact, APIs are pharmaceutical active ingredients that directly play a pharmacological role on the human body, and through the preparation and production of various excipients, APIs are eventually produced into finished drugs
in various dosage forms such as tablets, capsules, and injections.
For a long time, the API industry has occupied a very important position
in the pharmaceutical industry chain.
In recent years, with the continuous expansion of the production scale of China's API industry, the increasing variety and quantity of generic drugs, and the increase in environmental protection cost pressure, many domestic enterprises are actually increasing their layout
in this field.
Based on this, it is reasonable that the recent good news in the API industry
continues.
At present, the industry generally believes that the future growth space of the API sector is very broad, the supply and demand pattern of the industry will continue to be optimized, and at the same time, a large number of enterprises will usher in new growth in the API business, and related enterprises in the industrial chain will also usher in benefits
.
It is understood that in the API industry, pharmaceutical equipment is indispensable
.
In the different production links of APIs, a large number of production equipment with different missions are required, including reaction tanks, fermentation tanks, extraction equipment, sterilization filters, filter presses, etc
.
Therefore, as the upstream of the API industry, in the case of APIs ushering in a new blue ocean, the API pharmaceutical equipment industry will undoubtedly get more development opportunities
.
It is reported that in fact, in recent years, the demand for API equipment in China has increased significantly
.
According to statistics, the total industrial output value of the pharmaceutical equipment industry in 2015 was 21.
38 billion yuan, and by 2018, the total industrial output value has reached 28.
45 billion yuan; the forward-looking estimate is that the total industrial output value in 2019 will be 32.
03 billion yuan
.
In addition, in 2018, the output of all pharmaceutical equipment products in China, the output of APIs and equipment has also reached 25.
4%.
For example, extraction equipment increased by 33.
7%, heat exchange equipment increased by 6.
6%, and drying equipment increased by 5.
0%.
The market is constantly changing, and user needs are constantly changing and improving
.
Therefore, as the "engine" of APIs, API equipment enterprises need to continuously promote technological innovation and upgrading and keep pace with the times while ushering in the benefits, so as to build a strong moat and continuously meet the needs
of users.
It is reported that in order to cope with market competition and meet user needs, many domestic pharmaceutical equipment companies have begun to take actions
in improving cleanability, sealing, material and parameter control accuracy, cost reduction and efficiency increase.
If an enterprise has developed a new combination multi-effect water distiller
that can provide sterile pharmaceutical, injection, large infusion and biopharmaceuticals for the pharmaceutical industry.
According to the staff, the equipment can operate continuously for 240 days, saving 65%
of the energy in terms of saving water, saving industrial steam, and reducing the sewage pressure of the enterprise.
In addition, in order to cope with the problem of APIs, Chutian Technology also released the overall solution
of aseptic lyophilized API isolators.
According to reports, the overall solution is developed for the aseptic lyophilized API market, which can realize the continuity of lyophilization, discharging, crushing, mixing and dispensing processes, and the whole process is isolated and sealed, automation, which can help API users meet the requirements of green and low-carbon and ensure the quality
of drug production.
epilogue
In general, in the context of the broad prospects of the API industry, API equipment companies will undoubtedly usher in new development opportunities
.
It is worth noting that in line with the current policy and market development trends, the industry expects that creating green, energy-saving, environmentally friendly, efficient and intelligent equipment may become an important direction for the innovation and upgrading of
pharmaceutical enterprises.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
